Myriad Genetics (MYGN)
(Delayed Data from NSDQ)
$25.36 USD
+0.43 (1.72%)
Updated May 14, 2024 04:00 PM ET
After-Market: $25.35 -0.01 (-0.04%) 5:08 PM ET
3-Hold of 5 3
D Value C Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$25.36 USD
+0.43 (1.72%)
Updated May 14, 2024 04:00 PM ET
After-Market: $25.35 -0.01 (-0.04%) 5:08 PM ET
3-Hold of 5 3
D Value C Growth D Momentum D VGM
Zacks News
Sangamo Therapeutics (SGMO) in Focus: Stock Moves 13.6% Higher
by Zacks Equity Research
Sangamo Therapeutics (SGMO) shares rose nearly 14% in the last trading session, amid huge volumes.
Lexicon (LXRX) Looks Good: Stock Adds 7.6% in Session
by Zacks Equity Research
Lexicon (LXRX) was a big mover last session, as the company saw its shares rise more than 7% on the day amid huge volumes.
Here's Why Investors Should Buy Myriad Genetics Right Now
by Zacks Equity Research
Myriad Genetics' (MYGN) recent collaborations are encouraging. Also, the company banks on the GeneSight and EndoPredict portfolios.
Illumina Introduces NextSeq 550Dx, Updates Use of MiSeqDx
by Zacks Equity Research
Illumina (ILMN) expands NGS platform. The company has a solid diagnostic NGS portfolio, which includes NextSeq 550Dx and MiSeqDx.
Myriad Genetics' Latest Alliance to Boost GeneSight Reach
by Zacks Equity Research
Myriad Genetics' (MYGN) tie-up with Department of VA to assess the effectiveness of GeneSight test buoys optimism. Also, favorable results might boost GeneSight's customer base
Immunomedics (IMMU) Jumps: Stock Rises 5.4%
by Zacks Equity Research
Immunomedics (IMMU) was a big mover last session, as the company saw its shares more than 5% on the day amid huge volumes.
Here's Why Investors Should Buy Luminex (LMNX) Right Now
by Zacks Equity Research
Luminex (LMNX) continues to grow strong on innovation and product launches.
Haemonetics (HAE) Grows on Strong Plasma, Competition Rife
by Zacks Equity Research
Despite stiff competition, Haemonetics (HAE) grows on the back of its Plasma and Haemonetics Management franchises.
Quest Diagnostics, Clinical Genomics Ally, Oncology Strong
by Zacks Equity Research
Quest Diagnostics' (DGX) plan to distribute Clinical Genomics' FDA-approved InSure ONE is in line with the company's objective to lead in the high-potential oncology diagnostic market.
Ophthotech (OPHT) Jumps: Stock Rises 11.9%
by Zacks Equity Research
Ophthotech Corporation (OPHT) saw its shares rise nearly 12% on the day.
Medtronic Preliminary Sales Dip Y/Y, Hurricane Blow Lessens
by Zacks Equity Research
Divestiture of certain businesses to Cardinal Health induces year-over-year decline in Medtronic's (MDT) preliminary sales figure. However, impact of Maria is likely to be lighter on the company's finances.
BioTelemetry (BEAT) Q3 Earnings Miss, Revenues Meet Estimates
by Zacks Equity Research
A decline in gross and operating margin was a major drag for BioTelemetry (BEAT) in the third quarter.
Myriad Genetics (MYGN) Beats on Q1 Earnings & Revenues
by Zacks Equity Research
Myriad Genetics (MYGN) rides high on strength in Molecular diagnostics with significant contributions from GeneSight. Also, Hereditary cancer tests continue to witness year-over-year volume growth.
What's in the Cards for DaVita (DVA) Stock in Q3 Earnings?
by Zacks Equity Research
DaVita's (DVA) ongoing cost inflation might weigh on its margins in Q3. However, the Kidney Care business raises hope with steady investments in capital-efficient technologies.
Spectrum (SPPI) Earnings, Sales Beat Q3 Estimates
by Zacks Equity Research
Spectrum (SPPI) reports narrower-than-expected loss in Q3. Shares up.
Zoetis (ZTS) Beats on Q3 Earnings & Sales, Ups 2017 View
by Zacks Equity Research
Zoetis (ZTS) reported impressive third-quarter results beating estimates on both counts. Revenues were driven by strong demand for companion animal products worldwide.
Is a Beat in Store for Ionis (IONS) This Earnings Season?
by Zacks Equity Research
Ionis Pharmaceuticals (IONS) earned $50 million in milestone payments from Biogen. Spinraza had a strong third quarter as announced by Biogen in its earnings results.
Spectrum Pharmaceuticals (SPPI) Q3 Earnings: What's in Store?
by Zacks Equity Research
Spectrum Pharmaceuticals' (SPPI) Folotyn and Evomela drugs are expected to drive third-quarter sales. The company is progressing well with its pipeline candidates.
Is ACADIA (ACAD) Likely to Beat Earnings Estimates in Q3?
by Zacks Equity Research
ACADIA Pharmaceuticals' (ACAD) antipsychotic drug, Nuplazid, is expected to record strong sales in the third quarter despite increased prices backed by higher demand.
Can Molecular Diagnostics Drive Myriad's (MYGN) Q1 Earnings?
by Zacks Equity Research
Myriad Genetics (MYGN) is positioned to deliver solid results in Q1 on the back of the diversified Molecular Diagnostics portfolio with products like GeneSight and EndoPredict tests.
Zacks.com featured highlights: Tyson Foods, Movado Group, Myriad Genetics, PRA Health Sciences and Urstadt Biddle Properties
by Zacks Equity Research
Zacks.com featured highlights: Tyson Foods, Movado Group, Myriad Genetics, PRA Health Sciences and Urstadt Biddle Properties
Buy 5 Low-Beta Stocks & Forget Market Volatility
by Zacks Equity Research
We present a strategy that shows handsome return can be generated from investment in less risky stocks.
Myriad Genetics Presents Favorable riskScore Test Data
by Zacks Equity Research
Myriad (MYGN) presenting positive riskScore data at the NSGC conference in Columbus, OH buoys optimism. Notably, with riskScore the company intends to boost its myRisk Hereditary Cancer test suite.
Myriad Genetics Boosts myRisk Hereditary Cancer Test Suite
by Zacks Equity Research
Myriad Genetics (MYGN) introduces riskScore, a breast cancer prediction tool to broaden its myRisk hereditary cancer test offerings.
Myriad Genetics' EndoPredict Gets Positive Coverage Decision
by Zacks Equity Research
Considering Myriad Genetics' (MYGN) EndoPredict has been used clinically in more than 15,000 patients, we are confident about the growing adaptability of this test post the Medicare coverage approval.